BML Capital Management, LLC reported 15 positions worth $175.10M for the quarter ended Jun 30, 2026, up 16.7% on the prior quarter. It opened 1 new position, added to 5, trimmed 3 and exited 0. Its largest holding is Aclaris Therapeutics, Inc. at 36.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ENGN enGene Therapeutics Inc. | +6.67M | – | $11.54M | 6.59% |
| KHC Kraft Heinz Co | +340.0K | +272.0% | $8.03M | 6.27% |
| OM Outset Medical, Inc. | +617.5K | +32.5% | $2.67M | 6.22% |
| KMX Carmax Inc | +17.5K | +11.3% | $925.58K | 5.21% |
| CNTB Connect Biopharma Holdings Ltd | +164.4K | +40.2% | $391.27K | 0.779% |
| PMVP PMV Pharmaceuticals, Inc. | +10.0K | +0.2% | $13.40K | 4.08% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ENGN enGene Therapeutics Inc. | +6.67M | $11.54M | 6.59% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 11.98M | $63.35M | 36.18% | -2.28M | -16.0% | Reduced | 8.39% |
| 2 | AVIR Atea Pharmaceuticals, Inc. | Healthcare | 6.95M | $32.33M | 18.46% | -106.3K | -1.5% | Reduced | 8.67% |
| 3 | ENGN enGene Therapeutics Inc. | Healthcare | 6.67M | $11.54M | 6.59% | +6.67M | – | New | 9.57% |
| 4 | KHC Kraft Heinz Co | Consumer Staples | 465.0K | $10.98M | 6.27% | +340.0K | +272.0% | Added | 0.04% |
| 5 | OM Outset Medical, Inc. | Healthcare | 2.52M | $10.89M | 6.22% | +617.5K | +32.5% | Added | 13.4% |
| 6 | KMX Carmax Inc | Consumer Discretionary | 172.5K | $9.12M | 5.21% | +17.5K | +11.3% | Added | 0.12% |
| 7 | TLYS Tilly'S, Inc. | Consumer Discretionary | 2.15M | $9.03M | 5.16% | 0 | 0.0% | Unchanged | 9.27% |
| 8 | PMVP PMV Pharmaceuticals, Inc. | Healthcare | 5.33M | $7.14M | 4.08% | +10.0K | +0.2% | Added | 9.97% |
| 9 | TIL Instil Bio, Inc. | Healthcare | 645.6K | $4.96M | 2.84% | 0 | 0.0% | Unchanged | 9.52% |
| 10 | TGT Target Corp | Consumer Discretionary | 37.5K | $4.90M | 2.8% | 0 | 0.0% | Unchanged | 0.01% |
| 11 | ORMP Oramed Pharmaceuticals Inc. | Healthcare | 866.3K | $4.17M | 2.38% | -2.30M | -72.6% | Reduced | 2.1% |
| 12 | JANX Janux Therapeutics, Inc. | Healthcare | 155.0K | $2.38M | 1.36% | 0 | 0.0% | Unchanged | 0.25% |
| 13 | PLRX Pliant Therapeutics, Inc. | Healthcare | 1.55M | $1.76M | 1.01% | 0 | 0.0% | Unchanged | 2.5% |
| 14 | CNTB Connect Biopharma Holdings Ltd | Healthcare | 573.3K | $1.36M | 0.779% | +164.4K | +40.2% | Added | 0.91% |
| 15 | IMA ImageneBio, Inc. | Healthcare | 200.7K | $1.18M | 0.676% | 0 | 0.0% | Unchanged | 1.24% |
Tip. Select a row to see that position’s full history at BML Capital Management.
As of its Q2 2026 13F filing, BML Capital Management, LLC’s five largest positions were Aclaris Therapeutics, Inc. (ACRS) at 36.2%, Atea Pharmaceuticals, Inc. (AVIR) at 18.5%, enGene Therapeutics Inc. (ENGN) at 6.6%, Kraft Heinz Co (KHC) at 6.3%, Outset Medical, Inc. (OM) at 6.2% of the reported portfolio.
BML Capital Management, LLC reported a 13F portfolio worth $175.10M across 15 positions for Q2 2026. That is up 16.7% from the previous quarter.
Its largest purchases by value were enGene Therapeutics Inc. ($11.54M), Kraft Heinz Co ($8.03M), Outset Medical, Inc. ($2.67M). It opened 1 new positions.
Its largest sales by value were Aclaris Therapeutics, Inc. ($12.03M), Oramed Pharmaceuticals Inc. ($11.07M), Atea Pharmaceuticals, Inc. ($494.42K). It exited 0 positions entirely.
From the Form 13F-HR reports BML Capital Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.